Status:
RECRUITING
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Dapagliflozin or Usual Care
Lead Sponsor:
Region Stockholm
Collaborating Sponsors:
Karolinska Institutet
Conditions:
Atrial Fibrillation (AF)
Eligibility:
All Genders
55+ years
Phase:
PHASE3
Brief Summary
The goal of this clinical trial is to learn if drug dapagliflozin, a sodium-glucose transport-2 inhibitor, works to treat atrial fibrillation in adults. The main question it aims to answer is: • Does...
Eligibility Criteria
Inclusion
- Patients with AF on ECG who are planned for electrical cardioversion within 7-26 days from inclusion-date.
- Age ≥ 55 years.
- Provided written informed consent.
Exclusion
- Current treatment with an SGLT2 inhibitor.
- Prior/current diagnosis of heart failure.
- Type 1 diabetes mellitus.
- Estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73m2.
- Pulmonary vein isolation within preceding 3 months or planned pulmonary vein isolation during the study period (56 days).
- Contraindications to SGLT2 inhibitors.
- Any condition or circumstance in which the patient should not participate in the study according to the study investigator.
Key Trial Info
Start Date :
June 3 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
1600 Patients enrolled
Trial Details
Trial ID
NCT07187570
Start Date
June 3 2025
End Date
December 1 2027
Last Update
September 23 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Linköping university hosptial
Linköping, Sweden, 58225
2
Örebro University hospital
Örebro, Sweden, 70382
3
Södersjukhuset
Stockholm, Sweden, 11861
4
Karolinska University Hospital
Stockholm, Sweden, 14186